News

Home/News

Life Raft Group Collaborates on White Paper Published by Cancer Leaders

The Life Raft Group has been an integral part of a pan-cancer Working Group designed to determine consistent terminology around biomarker or mutational testing. The goal is to communicate to patients and the larger community in plain, patient friendly and consistent language what these terms mean, and how they impact on precision medicine.

By |2020-07-07T10:21:41-04:00July 7th, 2020|Advocacy, News|

COVID-19 – Resources GIST Patients Need

COVID-19 - Resources GIST Patients Need - Please know that the Life Raft Group is here to support you during this Coronavirus crisis. We will continue our daily services during this time and we will be distributing information and messages of hope through all our communication channels.

By |2020-07-07T08:21:19-04:00July 7th, 2020|News, Patient Support|

Blueprint Medicines Announces Publication in The Lancet Oncology

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST.

By |2020-06-30T11:57:14-04:00June 30th, 2020|Ayvakit, Clinical Trials, News|

Long-Term Survivor Stories – Chuck Korte & Dina Wiley

For GIST patients, long term survival is the ultimate goal. A number of factors may influence long term survival – some of these are demographic and clinical, like mutational subtype and genetic factors. However, there are a number of others that are perhaps more subtle, such as lifestyle, attitude, and access to treatment, experts, and advice.

By |2020-06-29T16:41:57-04:00June 25th, 2020|Member Stories, News, Newsletter|